J. Quentin Clemens, MD, explains how the annual AUA Census and the AUA Quality Registry (AQUA Registry) benefit practicing urologists.
The annual AUA Census and the AUA Quality Registry (AQUA Registry) are the association’s two primary data-gathering efforts, according to J. Quentin Clemens, MD, of the University of Michigan, Ann Arbor. In this interview, Dr. Clemens explains how these initiatives benefit practicing urologists. He was interviewed by Urology Times Editorial Consultant Gopal H. Badlani, MD, professor of urology at Wake Forest Baptist Medical Center, Winston-Salem, NC.
You were the chair of the AUA’s Data Committee. Please discuss the AUA’s data-gathering efforts and how they are of benefit to practicing urologists.
There are two main areas the committee has focused on. The first is the AUA Census, and we’ve already seen some benefits of participating in that related to topics such as advanced practice provider use and burnout in urology where this information can provide good ammunition to improve certain aspects of urology practice. The fact is that people with data tend to be the ones that run the discussion, so participating in the census should be viewed as something that could help all of urology and in particular practicing urologists.
The second is the AUA Quality Registry (AQUA Registry), which is a tool that can help practitioners meet many of the CMS requirements related to MACRA and MIPS. Very soon, urologists are going to see their Medicare pay cut if they don’t participate in these CMS programs. With AQUA, the AUA has set up an infrastructure to help make the process as easy as possible, and this includes having measures that are specific to urology as opposed to measures that are very tangential, such as tobacco cessation and hypertension management.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.